Trevi Therapeutics to Report Q3 2023 Financial Results and Provide a Corporate Update on November 9, 2023
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for difficult to treat patients with chronic cough in idiopathic pulmonary fibrosis (IPF), refractory chronic cough, and prurigo nodularis, today announced that senior management will host…
Vanda Pharmaceuticals to Announce Third Quarter 2023 Financial Results on November 8, 2023
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the third quarter 2023 on Wednesday, November 8, 2023, after the market closes. Vanda will host a conference call at 4:30 PM ET on Wednesday, November 8, 2023, during…